Skip to content

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00049751
Enrollment
3000
Registered
2002-11-14
Start date
2002-09-30
Completion date
Unknown
Last updated
2006-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).

Interventions

DRUGAdalimumab

Sponsors

Abbott
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Inclusion: * Subjects must meet ACR criteria for diagnosis of RA for at least 3 months, must meet ACR Functional Class I, II or III (1992 criteria) and must have a confirmed diagnosis of active moderate to severe rheumatoid arthritis as defined by 6 or more swollen joints and 9 or more tender joints; * must also have DAS of 3.2 or greater at study entry, * normal laboratory parameters and ESR \>20, * satisfactory response or intolerance to one or more prior DMARDs and * be willing and able to give informed consent. Exclusion: * Previous treatment with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibodies resulting in persistent CD4 lymphopenia, * history of acute inflammatory joint disease other than RA, * prior treatment with cyclophosphamide or chlorambucil, * prior treatment with intravenous immunoglobulin within 70 days, * history of malignant lymphoma, * history of uncontrolled diabetes, * unstable ischemic heart disease, * active inflammatory bowel disease, * active peptic ulcer disease or stroke, * positive HIV status, * positive serology for Hepatitis B or C, * no previous history of tuberculosis or listeria infection, * no previous history of cancer other than successfully treated skin cancer; * women can not be pregnant or be breastfeeding

Design outcomes

Primary

MeasureTime frame
Change in disease activity score at visit week 12 as compared to baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026